Two potential target genes, GSK3B and BACE1, have been deemed possible candidates as disease-modifying agents for Alzheimer’s disease due to their involvement in amyloid-beta and tau production, as well as their ability to enhance cognitive functions [26]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.